These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 25535825)

  • 1. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital.
    Di Gregorio S; Perazzi B; Ordoñez AM; De Gregorio S; Foccoli M; Lasala MB; García S; Vay C; Famiglietti A; Mollerach M
    Microb Drug Resist; 2015 Feb; 21(1):25-34. PubMed ID: 25535825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital.
    da Costa TM; Morgado PG; Cavalcante FS; Damasco AP; Nouér SA; Dos Santos KR
    PLoS One; 2016; 11(8):e0160506. PubMed ID: 27575698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units.
    Hu HC; Kao KC; Chiu LC; Chang CH; Hung CY; Li LF; Liu TP; Lin LC; Chen NH; Huang CC; Yang CT; Lu JJ
    BMC Infect Dis; 2015 Oct; 15():444. PubMed ID: 26497595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of a globally disseminated hypervirulent clone, Staphylococcus aureus CC121, with reduced vancomycin susceptibility in community settings in China.
    Shen P; Zhou K; Wang Y; Song J; Liu Y; Zhou Y; Xiao Y
    J Antimicrob Chemother; 2019 Sep; 74(9):2537-2543. PubMed ID: 31203362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
    Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
    BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center.
    Maor Y; Rahav G; Belausov N; Ben-David D; Smollan G; Keller N
    J Clin Microbiol; 2007 May; 45(5):1511-4. PubMed ID: 17344363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.
    Maor Y; Hagin M; Belausov N; Keller N; Ben-David D; Rahav G
    J Infect Dis; 2009 Mar; 199(5):619-24. PubMed ID: 19199552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and clinical prognosis of heteroresistant vancomycin-intermediate Staphylococcus aureus in a tertiary care center in China.
    Wang Y; Hu YJ; Ai XM; Xu HT; Sun TY
    Chin Med J (Engl); 2013 Feb; 126(3):505-9. PubMed ID: 23422115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New patterns of methicillin-resistant Staphylococcus aureus (MRSA) clones, community-associated MRSA genotypes behave like healthcare-associated MRSA genotypes within hospitals, Argentina.
    Egea AL; Gagetti P; Lamberghini R; Faccone D; Lucero C; Vindel A; Tosoroni D; Garnero A; Saka HA; Galas M; ; Bocco JL; Corso A; Sola C
    Int J Med Microbiol; 2014 Nov; 304(8):1086-99. PubMed ID: 25240872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus.
    Harigaya Y; Ngo D; Lesse AJ; Huang V; Tsuji BT
    BMC Infect Dis; 2011 Oct; 11():287. PubMed ID: 22026752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
    Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
    J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
    Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
    Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus among blood isolates in Korean hospitals.
    Kang YR; Chung DR; Baek JY; Kim SH; Cho SY; Ha YE; Kang CI; Peck KR; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):464-466. PubMed ID: 27720209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China.
    Liu C; Chen ZJ; Sun Z; Feng X; Zou M; Cao W; Wang S; Zeng J; Wang Y; Sun M
    J Microbiol Immunol Infect; 2015 Oct; 48(5):490-6. PubMed ID: 24767415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.